MicroRNA regulates process vital to placenta growth in early pregnancy

February 25, 2020

TAMPA, Fla (Feb. 25, 2020) -- Abnormal formation and growth of the placenta is considered an underlying cause of various pregnancy complications such as miscarriages, preeclampsia and fetal growth restriction. Yet, much remains to be learned about molecular mechanisms regulating this blood-vessel rich organ vital to the health of a pregnant woman and her growing fetus.

A new study by University of South Florida Health (USF Health) Morsani College of Medicine researchers has discovered how a very large human non-protein coding gene regulates epithelial-to-mesenchymal transition (EMT) - a process that contributes to placental implantation during early pregnancy as well as cancer progression and spread.

The USF Health researchers used a powerful genome editing technology called CRISPR (shorthand for "CRISPR-dCas9) to activate all of the chromosome 19 microRNA cluster (known as C19MC), so they could study the gene's function in early pregnancy. C19MC -- one of the largest microRNA gene clusters in the human genome -- is normally turned off and becomes expressed only in the placenta, embryonic stem cells and certain cancers.

In their cell model study, published Feb. 20 in Scientific Reports, a Nature research journal, the USF Health team showed that robustly activating C19MC inhibited EMT.

But when cells from which the placenta arises (trophoblasts) were exposed to hypoxia - a lack of oxygen like that occurring in early placental development -- C19MC expression was significantly reduced, the researchers found. This loss of C19MC function then freed the trophoblasts to differentiate from stem-like epithelial cells into mesenchymal cells that can migrate and invade much like metastatic tumors.

"We were the first to use CRISPR to efficiently activate the entire gene, not just a few regions of this huge gene, in human cell lines," said the paper's senior author Hana Totary-Jain, PhD, an associate professor in the Department of Molecular Pharmacology and Physiology, USF Health Morsani College of Medicine. "Our study indicates C19MC plays a key role in regulating many genes important in early implantation and placental development and function. The regulation of these genes are critical for proper fetal growth."

Dr. Totary-Jain and others in her department collaborated with colleagues in the medical college's Department of Obstetrics and Gynecology on the project.

The USF Health study offers new insight into how trophoblasts interact with the maternal uterine environment to become more invasive or less invasive in the formation of the placenta, said co-author Umit Kayisli, PhD, a USF Health professor of obstetrics and gynecology. "More research on microRNA expression and how it inhibits the epithelial-to-mesenchymal transition may help us better understand and control preeclampsia and fetal growth restriction, which account for 5-to-10 percent of all pregnancy complications and premature births."

EMT happens early in the formation of the placenta, an organ which attaches to the lining of the uterus during pregnancy and supplies oxygen and nutrients from mother to the growing fetus. During the first trimester, fetal trophoblasts penetrate the maternal uterine lining and modify its blood vessels. This remodeling of the mother's spiral arteries allows oxygenated blood to flow from the mother to fetus.

However, the trophoblast invasion prompted by EMT is a tightly coordinated balancing act. If the invasion is too shallow to adequately remodel the maternal blood vessels, preeclampsia and fetal growth restriction can occur. Invasion that progresses too deeply -- beyond normal anchoring of the placenta to the uterine wall - leads to placenta accreta, a rare condition that can cause dangerous bleeding and often require pregnancy termination.

"You need the EMT process, but at some point it needs to stop to prevent adverse pregnancy outcomes," Dr. Totary-Jain said. "You really need a balance between not enough invasion and too much invasion, and C19MC is important in maintaining that balance."

Investigating the effects of altered C19MC expression on cell differentiation and trophoblast invasion has implications not only for a better understanding of normal and abnormal placenta development, but also for cancer and stem cell research, Dr. Totary-Jain added.
USF Health's mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and the physicians of USF Health, the largest multispecialty group practice on Florida's west coast. The University of South Florida, established in 1956 and located in Tampa, is a high-impact, global research university dedicated to student success. USF ranks in the top 25 nationally for research expenditures among public universities, according to the National Science Foundation. In 2018, the Florida Board of Governors designated USF as a Preeminent State Research University, placing USF in the most elite category among the state's 12 public universities.

University of South Florida (USF Health)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.